Is Agilent Technologies, Inc. overvalued or undervalued?

As of 17 October 2025, Agilent Technologies, Inc. has moved from a very expensive valuation to fair. The company is currently fairly valued based on its financial metrics, with a P/E ratio of 25, an EV to EBITDA of 18.73, and a Price to Book Value of 5.36. In comparison, peers such as Edwards Lifesciences Corp. have a higher P/E of 31.17, while DexCom, Inc. is even more expensive with a P/E of 53.65, indicating that Agilent is relatively more attractively priced within its industry.
Despite its fair valuation, Agilent's recent stock performance has lagged behind the S&P 500, returning only 3.27% over the past year compared to the S&P 500's 14.08%. However, it has shown stronger returns over shorter periods, with a 1-month return of 11.99% versus the S&P 500's 0.96%. Overall, Agilent's valuation appears reasonable given its competitive positioning and performance metrics.